Antiphospholipid Antibodies Are Common in Patients Referred for Percutaneous Patent Foramen Ovale Closure

Catheterization and Cardiovascular Interventions

Volumn 61, Issue 1, 2004, Pages 123-127

  Dodge, Stephen M ^a,b   Hassell, Kathryn ^a,b   Anderson, C Alan ^a,b   Keller, Jana ^a,b   Groves, Bertron ^a,b   Carroll, John D ^a,b  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO HOSPITAL   (United States)

Author keywords

Atrial heart septal defects; Blood coagulation disorders; Cerebrovascular accident; Paradoxical embolism; Thrombophilia

Indexed keywords

LIPOPROTEIN A; PHOSPHOLIPID ANTIBODY;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ARTICLE; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DYSFIBRINOGENEMIA; FEMALE; HEART ATRIUM SEPTUM DEFECT; HUMAN; HYPERCOAGULABILITY; HYPERHOMOCYSTEINEMIA; LIPOPROTEIN BLOOD LEVEL; MALE; PERCUTANEOUS CORONARY INTERVENTION; RISK FACTOR; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; COHORT STUDIES; FEMALE; HEART CATHETERIZATION; HEART SEPTAL DEFECTS, ATRIAL; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; THROMBOPHILIA;

EID: 0346101541     PISSN: 15221946     EISSN: None     Source Type: Journal    
DOI: 10.1002/ccd.10754     Document Type: Article

References (28)

1. Hagen PT, Scholz DG, Edwards WD. Incidence and size of patent foramen ovale during the first 10 decades of life: an autopsy study of 965 normal hearts. Mayo Clin Proc 1984;59:17-20.
2. Meissner I, Whisnant JP, Khandheria BK, Spittell PC, O'Fallon WM, Pascoe RD, Enriquez-Sarano M, Seward JB, Covalt JL, Sicks JD, Wiebers DO. Prevalence of potential risk factors for stroke assessed by transesophageal echocardiography and carotid ultrasound: the SPARC study. Mayo Clin Proc 1999;74:862-869.
3. Johnson BI. Paradoxical embolism. J Clin Pathol 1951;4:316-332.
4. Overell JR, Bono I, Lees KR. Interatrial septal abnormalities and stroke: a meta-analysis of case-control studies. Neurology 2000;55:1172-1179.
5. Orgera MA, O'Malley PG, Taylor AJ. Secondary prevention of cerebral ischemia in patent foramen ovale: systematic review and meta-analysis. Southern Med J 2001;94:699-703.
6. Mas J-L, Arquizan C, Lamy C, Zuber M, Cabanes L, Derumeaux G, Coste J, for the Patent Foramen Ovale and Atrial Septal Aneurysm Study Group. Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both. N Engl J Med 2001;345:1740-1746.
7. Dearani JA, Ugurlu BS, Danielson GK, Daly RC, McGregor CGA, Mullany CJ, Puga FJ, Orszulak TA, Anderson BJ, Brown RD, Schaff HV. Surgical patent foramen ovale closure for prevention of paradoxical embolism-related cerebrovascular ischemic events. Circulation 1999;100(Suppl 2):II171-II175.
8. Hung J, Landzberg MJ, Jenkins KJ, King MEE, Lock JE, Palacios IF, Lang P. Closure of patent foramen ovale for paradoxical emboli: intermediate-term risk of recurrent neurological events following transcatheter device placement. J Am Coll Cardiol 2000;35:1311-1316.
9. Windecker S, Wahl A, Chatterjee T, Garachemani A, Eberli FR, Seiler C, Meier B. Percutaneous closure of patent foramen ovale in patients with paradoxical embolism: long-term risk of recurrent thromboembolic events. Circulation 2000;101:893-898.
10. Bushnell CD, Goldstein LB. Diagnostic testing for coagulopathies in patients with ischemic stroke. Stroke 2000;31:3067-3078.
11. Thomas RH. Hypercoagulability syndromes. Arch Intern Med 2001;161:2433-2439.
12. Federman DG, Kirsner RS. An update on hypercoagulable disorders. Arch Intern Med 2001;161:1051-1056.
13. van Beynum IM, Smeitink JAM, den Heijer M, te Poele Pothoff MTWB, Blom HJ. Hyperhomocysteinemia: a risk factor for ischemic stroke in children. Circulation 1999;99:2070-2072.
14. Milionis HJ, Winder AF, Mikhailidis DP. Lipoprotein (a) and stroke. J Clin Pathol 2000;53:487-496.
15. Côté HCF, Lord ST, Pratt KP. γ-chain dysfibrinogenemias: molecular structure-function relationships of naturally occurring mutations in the g chain of human fibrinogen. Blood 1998;92:2195-2212.
16. Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. N Engl J Med 2002;346:752-763.
17. Greaves M. Antiphospholipid antibodies and thrombosis. Lancet 1999;353;1348-1353.
18. Petri M. Epidemiology of the antiphospholipid antibody syndrome. J Autoimmun 2000;15:145-151.
19. Chaturvedi S. Coagulation abnormalities in adults with cryptogenic stroke and patent foramen ovale. J Neuro Sci 1998;160:158-160.
20. Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette J-C, Brey R, Derksen R, Harris EN, Hughes GRV, Triplett DA, Khamashta MA. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999;42:1309-1311.
21. Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update. Thromb Haemost 1995;74:1185-1190.
22. Braun MU, Fassbender D, Schoen SP, Haass M, Schrader R, Scholtz W, Strasser RH. Transcatheter closure of patent foramen ovale in patients with cerebral ischemia. J Am Coll Cardiol 2002;39:2019-2025.
23. Nkomo VT, Theuma P, Maniu CV, Chandrasekaran K, Miller FA, Schaff HV, Petty GW, Miller TD. Patent foramen ovale transcatheter closure device thrombosis. Mayo Clin Proc 2001;76:1057-1061.
24. Vanderheyden M, Willaert W, Claessens P, Branders I, Ex P, Vermeersch P. Thrombosis of a patent foramen ovale device: thrombolytic management. Catheter Cardiovasc Interv 2002;56:522-526.
25. Stangl V, Stangl K, Bohm J, Felix SB. Thrombus formation after catheter closure of an atrial septal defect with a clamshell device. Ann Thorac Surg 2000;69:1956.
26. La Rosee K, Deutsch HJ, Schnabel P, Schneider CA, Burkhard-Meier C, Hopp HW. Thrombus formation after transcatheter closure of ASD. Am J Cardiol 1999;84:356-359.
27. Acar P, Aggoun Y, Abdel-Massih T. Thrombus after transcatheter closure of ASD with an Amplatzer septal occluder assessed by three dimensional echocardiographic reconstruction. Heart 2002;88:52.
28. Gastmann O, Werner GS, Babic UU, Figulla HR. Thrombus formation on transcatheter ASD occluder device in a patient with coagulation factor XII deficiency. Cathet Cardiovasc Diagn 1998;43:81-83.